Tech Company Financing Transactions

Pear Therapeutics Funding Round

On 1/7/2019, Pear Therapeutics raised $64 million in Series C funding from Temasek Holdings, 5AM Ventures and Arboretum Ventures.

Transaction Overview

Company Name
Pear Therapeutics
Announced On
1/7/2019
Transaction Type
Venture Equity
Amount
$64,000,000
Round
Series C
Investors

Temasek Holdings (Lead Investor)

5AM Ventures (Andrew Schwab)

Arboretum Ventures (Timothy Petersen)

Blue Water Life Science Fund

Bridge Builders Collaborative

Edbi

JAZZ Venture Partners (Zack Lynch)

Novartis Venture Fund

Trustbridge Partners

Proceeds Purpose
The financing will allow Pear to support the global commercialization of the reSET suite of products, fund the company's clinical-stage pipeline, and opportunistically acquire additional assets.

Company Information

Company Status
Private & Independent
Industry
Software
Mailing Address
200 State St.
Boston, MA 02109
USA
Phone
Undisclosed
Website
www.peartherapeutics.com
Email Address
[email protected]
Overview
Pear Therapeutics' patented eFormulation approach combines mobile health apps with supplements, medical foods, and pharmaceuticals, to create more efficacious treatment solutions. eFormulations are simple to use. A software access code on the product packaging provides access to Pear's health apps.
Profile
Pear Therapeutics LinkedIn Company Profile
Social Media
Pear Therapeutics Company Twitter Account
Company News
Pear Therapeutics News
Facebook
Pear Therapeutics on Facebook
YouTube
Pear Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Corey McCann
  Corey McCann LinkedIn Profile  Corey McCann Twitter Account  Corey McCann News  Corey McCann on Facebook
Chief Medical Officer
Yuri Maricich
  Yuri Maricich LinkedIn Profile  Yuri Maricich Twitter Account  Yuri Maricich News  Yuri Maricich on Facebook
Chief Operating Officer
Christopher Guiffre
  Christopher Guiffre LinkedIn Profile  Christopher Guiffre Twitter Account  Christopher Guiffre News  Christopher Guiffre on Facebook
Vice President
Catherine Cushenberry
  Catherine Cushenberry LinkedIn Profile  Catherine Cushenberry Twitter Account  Catherine Cushenberry News  Catherine Cushenberry on Facebook
Vice President
Mark Deeg
  Mark Deeg LinkedIn Profile  Mark Deeg Twitter Account  Mark Deeg News  Mark Deeg on Facebook
Vice President
Michael Pace
  Michael Pace LinkedIn Profile  Michael Pace Twitter Account  Michael Pace News  Michael Pace on Facebook
VP - Bus. Development
Julia Strandberg
  Julia Strandberg LinkedIn Profile  Julia Strandberg Twitter Account  Julia Strandberg News  Julia Strandberg on Facebook
VP - Bus. Development
Alex Waldron
  Alex Waldron LinkedIn Profile  Alex Waldron Twitter Account  Alex Waldron News  Alex Waldron on Facebook
VP - Engineering
Gordon Kass
  Gordon Kass LinkedIn Profile  Gordon Kass Twitter Account  Gordon Kass News  Gordon Kass on Facebook
VP - General Counsel
Ronan O'Brien
  Ronan O'Brien LinkedIn Profile  Ronan O'Brien Twitter Account  Ronan O'Brien News  Ronan O'Brien on Facebook
VP - Human Resources
Kathy Jeffery
  Kathy Jeffery LinkedIn Profile  Kathy Jeffery Twitter Account  Kathy Jeffery News  Kathy Jeffery on Facebook
VP - Marketing
Kirsten Carlson
  Kirsten Carlson LinkedIn Profile  Kirsten Carlson Twitter Account  Kirsten Carlson News  Kirsten Carlson on Facebook
VP - Product Management
Kathleen Bauman
  Kathleen Bauman LinkedIn Profile  Kathleen Bauman Twitter Account  Kathleen Bauman News  Kathleen Bauman on Facebook
VP - Product Management
Erin Brenner
  Erin Brenner LinkedIn Profile  Erin Brenner Twitter Account  Erin Brenner News  Erin Brenner on Facebook
VP - Regulatory Affairs
Steve Sherman
  Steve Sherman LinkedIn Profile  Steve Sherman Twitter Account  Steve Sherman News  Steve Sherman on Facebook
VP - Sales
Brian Prunier
  Brian Prunier LinkedIn Profile  Brian Prunier Twitter Account  Brian Prunier News  Brian Prunier on Facebook

 

 

Browse more venture capital transactions:

Prev: 1/7/2019: Boom Supersonic venture capital transaction
Next: 1/7/2019: Sophia Genetics venture capital transaction

 

Share this article

 

Where The Data Comes From

We report on tech company VC transactions. All VC database entries reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.